Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13207 | 0.97 | L3MBTL3 (0.46) | L3MBTL3L3MBTL1MBTD1HRH3KDM4E | |
| SCHEMBL6464543 | 0.94 | HRH3 (0.46) | L3MBTL3L3MBTL1MBTD1HRH3KDM4E | |
| SCHEMBL14528417 | 0.93 | L3MBTL3 (0.43) | L3MBTL3L3MBTL1MBTD1HRH3KDM4E | |
| SCHEMBL14907095 | 0.91 | L3MBTL3 (0.49) | L3MBTL3L3MBTL1HRH3KDM4EALDH1A1 | |
| SCHEMBL25672747 | 0.89 | L3MBTL3 (0.47) | L3MBTL3L3MBTL1HRH3KDM4EALDH1A1 | |
| SCHEMBL5004073 | 0.89 | HRH3 (0.41) | L3MBTL3L3MBTL1MBTD1HRH3KDM4E | |
| SCHEMBL16877337 | 0.87 | L3MBTL3 (0.43) | L3MBTL3L3MBTL1MBTD1HRH3KDM4E | |
| SCHEMBL18207732 | 0.87 | SMN1; SMN2 (0.48) | L3MBTL3L3MBTL1HRH3KDM4EALDH1A1 | |
| SCHEMBL14862483 | 0.86 | SMN1; SMN2 (0.50) | L3MBTL3L3MBTL1HRH3ALDH1A1HPGD | |
| SCHEMBL14529673 | 0.84 | KDM2B (0.36) | L3MBTL3L3MBTL1HRH3KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220370431-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2022-11-24 | — | — | US | claimed |
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| CN-117736199-A | 6H-dibenzo [ b, d ] pyran derivative substituted by 3-position oxygen-containing group, and preparation method and application thereof | 西安交通大学 | 2024-03-22 | — | — | CN | disclosed |
| US-11369599-B2 | Melt-extruded solid dispersions containing an apoptosis-inducing agent | ABBVIE INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
| EP-2986616-B1 | TRICYCLIC TRIAZOLIC COMPOUNDS AS SIGMA RECEPTORS LIGANS | ESTEVE LABOR DR (ES) | 2017-03-29 | — | — | EP | disclosed |
| EP-2499146-B1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2016-09-21 | — | — | EP | disclosed |
| EP-2794608-B1 | TETRAAZA-CYCLOPENTA[A]INDENYL AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS | MERCK PATENT GMBH (DE) | 2016-09-14 | — | — | EP | disclosed |
| EP-2435433-B1 | (DIHYDRO)IMIDAZOISO[5,1-A]QUINOLINES AS FSH RECEPTOR AGONISTS FOR THE TREATMENT OF FERTILITY DISORDERS | MERCK SHARP & DOHME (NL) | 2013-08-28 | — | — | EP | disclosed |
| EP-2109605-B1 | 2- [(PHENYLAMINO) -PYRIMIDIN-4YLAMIN0] -CYCLOPENTANE CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF KINASES OF THE CELL CYCLE FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2013-02-20 | — | — | EP | disclosed |
| US-20120238545-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2012-09-20 | — | — | US | disclosed |
| US-8071587-B2 | (Dihydro)imidazoiso[5,1-A]quinolines | N. V. ORGANON (NL) | 2011-12-06 | — | — | US | disclosed |
| WO-2011120025-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011095434-A1 | TETRAHYDRO-PYRAN DERIVATIVES AGAINST NEUROLOGICAL ILLNESSES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-11 | — | — | WO | disclosed |
| US-20100324021-A1 | (DIHYDRO)IMIDAZOISO[5,1-A]QUINOLINES | N.V. ORGANON (NL) | 2010-12-23 | — | — | US | disclosed |
| WO-2010136438-A1 | (DIHYDRO) IMIDAZOISO (5, 1-A) QUINOLINES AS FSH RECEPTOR AGONISTS FOR THE TREATMENT OF FERTILITY DISORDERS | N.V. ORGANON (NL) | 2010-12-02 | — | — | WO | disclosed |
| US-20090163465-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
| WO-2007053498-A1 | COMPOUNDS USEFUL AS ANTAGONISTS OF CCR2 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| EP-0997474-B1 | Antithrombotic agents | PFIZER (US) | 2003-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220370431-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | L3MBTL3 114/4885L3MBTL1 218/4885MBTD1 2066/4885 |
| US-20120238545-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | PI4KB, MTOR, PI4KA | L3MBTL3 4599/4885L3MBTL1 4614/4885MBTD1 3743/4885 |
| US-20100324021-A1 | (DIHYDRO)IMIDAZOISO[5,1-A]QUINOLINES | NQO2, IPO5, SCN5A | L3MBTL3 4055/4885L3MBTL1 3294/4885MBTD1 3157/4885 |
| US-20090163465-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | L3MBTL3 1217/4885L3MBTL1 849/4885MBTD1 3133/4885 |
| US-11369599-B2 | Melt-extruded solid dispersions containing an apoptosis-inducing agent | BCL2, BAX, BCL2L1 | L3MBTL3 1812/4885L3MBTL1 1172/4885MBTD1 354/4885 |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | L3MBTL3 1217/4885L3MBTL1 849/4885MBTD1 3133/4885 |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, F13B, GRN | L3MBTL3 1368/4885L3MBTL1 718/4885MBTD1 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.